Intervention Protocol

You have free access to this content

Belatacept for kidney transplant recipients

  1. Philip Masson1,*,
  2. Lorna Henderson2,
  3. Jeremy R Chapman3,
  4. Jonathan C Craig1,4,
  5. Angela C Webster1,4,5

Editorial Group: Cochrane Renal Group

Published Online: 15 AUG 2013

DOI: 10.1002/14651858.CD010699


How to Cite

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010699. DOI: 10.1002/14651858.CD010699.

Author Information

  1. 1

    The University of Sydney, Sydney School of Public Health, Sydney, Australia

  2. 2

    Royal Infirmary of Edinburgh, Department of Renal Medicine, Edinburgh, UK

  3. 3

    Westmead Millennium Institute, The University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead, NSW, Australia

  4. 4

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  5. 5

    The University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead Millennium Institute, Westmead, NSW, Australia

*Philip Masson, Sydney School of Public Health, The University of Sydney, Sydney, Australia. philip_masson@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 15 AUG 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objectives of this review are to:

  1. Compare the relative efficacy of belatacept versus any other immunosuppressive co-intervention for preventing acute rejection and maintaining kidney transplant function, and composite kidney transplant and recipient survival.
  2. Compare the incidence of several adverse events: Post-transplant lymphoproliferative disorder; other malignancies; IF/TA; infective complications; deterioration in blood pressure, lipid and glycaemic control.
  3. Assess any variation in effects by study, intervention and recipient characteristics, including: differences in pre-transplant Epstein-Barr virus status; belatacept dosing regimen; and donor-category (living, standard criteria deceased, or extended criteria deceased).